Sofpironium bromide

Sofpironium bromide
Clinical data
Trade namesEcclock, others
Other namesBBI-4000, BBI 4000
AHFS/Drugs.comMonograph
License data
Routes of
administration		Topical
Drug classAnticholinergic
ATC code
  • None
Legal status
Legal status
Identifiers
  • [(3R)-1-(2-Ethoxy-2-oxoethyl)-1-methylpyrrolidin-1-ium-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate bromide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC22H32BrNO5
Molar mass470.404 g·mol−1
3D model (JSmol)
  • CCOC(=O)C[N+]1(CC[C@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C.[Br-]
  • InChI=1S/C22H32NO5.BrH/c1-3-27-20(24)16-23(2)14-13-19(15-23)28-21(25)22(26,18-11-7-8-12-18)17-9-5-4-6-10-17;/h4-6,9-10,18-19,26H,3,7-8,11-16H2,1-2H3;1H/q+1;/p-1/t19-,22+,23?;/m1./s1
  • Key:FIAFMTCUJCWADZ-JOFREBOKSA-M

Sofpironium bromide, sold under the brand name Ecclock among others, is a medication used to treat hyperhidrosis (excessive sweating).[1] Sofpironium bromide is an anticholinergic agent that is applied to the skin.[1]

It was approved in Japan in 2020, for the treatment of primary axillary hyperhidrosis.[2] It was approved for medical use in the United States in June 2024.[1][3][4]

Medical uses

[edit]

Sofpironium bromide is indicated for the treatment of primary axillary hyperhidrosis.[1]

Mechanism of action

[edit]

The pharmacodynamics of sofpironium bromide are unknown.[1]

Society and culture

[edit]
[edit]

It was approved for medical use in Japan in November 2020,[5] and in the United States in June 2024.[1][6]

Brand names

[edit]

Sofpironium bromide is the international nonproprietary name.[7]

It is sold under the brand name Ecclock in Japan and under the brand name Sofdra in the US.

References

[edit]
  1. ^ a b c d e f g "Sofdra- sofpironium bromide gel". DailyMed. 26 August 2024. Retrieved 2 September 2024.
  2. ^ Paik J (December 2020). "Sofpironium Bromide: First Approval". Drugs. 80 (18): 1981–1986. doi:10.1007/s40265-020-01438-1. PMID 33236266. S2CID 227155835.
  3. ^ "Drug Approval Package: Sofdra". U.S. Food and Drug Administration (FDA). 17 July 2024. Retrieved 2 September 2024.
  4. ^ "FDA Approves Sofdra topical gel" (Press release). Botanix Pharmaceuticals. 20 June 2024. Archived from the original on 20 June 2024. Retrieved 20 June 2024.
  5. ^ "Brickell Biotech Announces Launch Date for Sofpironium Bromide Gel, 5% (Ecclock) in Japan by its Development Partner, Kaken Pharmaceutical" (Press release). Brickell Biotech. 18 November 2020. Retrieved 2 September 2024 – via GlobeNewswire.
  6. ^ "Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 1 October 2024. Retrieved 29 November 2024.
  7. ^ World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 77". WHO Drug Information. 31 (1). hdl:10665/330984.

Further reading

[edit]
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Sofpironium_bromide&oldid=1263539737"